Drug Profile
Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical
Alternative Names: LJPC-6417Latest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator La Jolla Pharmaceutical Company
- Class
- Mechanism of Action Bone morphogenetic protein receptor type I antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrodysplasia ossificans progressiva
Most Recent Events
- 22 Aug 2022 La Jolla Pharmaceutical Company has been acquired by Innoviva
- 16 Jul 2016 No recent reports of development identified for research development in Fibrodysplasia-ossificans-progressiva in USA
- 18 Apr 2013 Early research in Fibrodysplasia ossificans progressiva in USA (unspecified route)